Abstract:Alcohol-associated hepatitis (AH) is associated with increased short-term mortality in the presence of infections and rapid onset of extrahepatic organ failure driven by intestinal dysbiosis. [ 1 ] Deleterious modifications of the gut microbiota (GM) which include bacteria, fungi, and viral groups in the presence of alcohol are well documented across multiple studies globally. [ 2 ] Gut microbiota contributes to individual susceptibility to alcohol-related liver disease (ALD) and AH through detrimental changes to immune signaling, functional metabolism, and the gut–brain axis. [ 3 ] Specific bacterial taxa have been shown to affect the promotion, progression, and clinical events associated with ALD and AH. For example, in the presence of alcohol, pathogenic bacteria, such as Acinetobacter baumannii enhance their virulence. Alcohol use reduces bacterial diversity, decreases the abundance of beneficial Bacteroidetes, and increases that of pathogenic Proteobacteria, as demonstrated by a significant decrease in Ruminococcaceae and an increase in both Lachnospiraceae and Enterobacteriaceae. [ 4 , 5 ] Alcohol-induced GM dysbiosis leads to liver damage owing to the proliferation of harmful microorganisms that produce exotoxins. One such exotoxin, cytolysin, secreted by Enterococcus faecalis , can directly harm hepatocytes. A higher presence of cytolysin-positive Enterococcus faecalis correlates with greater severity of liver disease and elevated mortality rates in patients with AH. [ 6 ] Specific GM, their interactions, and metabolites are associated with complications of AH and the corresponding treatment outcomes. [ 7 ] Similarly, fungal dysbiosis and fungal metabolites affect the severity of AH. The burgeoning field of research on fungal dysbiosis and proliferation of specific fungal species in ALD has revealed significant findings. Elevated serum levels of anti- Saccharomyces cerevisiae immunoglobulin G antibodies, which indicate a systemic immune response to fungi and their byproducts, are observed in patients with alcohol use disorder and ALD. In patients with AH, heightened serum anti- Saccharomyces cerevisiae immunoglobulin G antibodies levels are associated with increased mortality. Additionally, a higher relative abundance of specific fungal species, such as Candida albicans and Malassezia restricta in the gut, correlates with more severe liver injury and increased mortality in ALD patients. [ 8–10 ] Preliminary studies have shown that patients with ALD and AH can benefit from GM modulation. Clinical trials have explored the use of fecal microbiota transplantation (FMT) to alter the gut microbiome of patients with AH. Studies have demonstrated that AH patients who received FMT from healthy donors exhibited lower rates of alcohol relapse, infections, or hospitalizations; higher rates of resolution of hepatic encephalopathy and ascites; and improved survival in both the short and long term when compared to standard medical care, including pentoxifylline therapy. [ 11–13 ] Another randomized controlled study included 120 patients with AH who received either prednisolone or a healthy donor FMT. Patients receiving FMT had better 90-day survival rates and a reduced incidence of infections compared to those receiving prednisolone. [ 14 ] Probiotics have been shown to improve clinical outcomes in alcohol-associated cirrhosis, and foundational evidence supports their positive effects on GM. Preliminary evidence also supports the beneficial effects of probiotic therapy on GM in AH. [ 15 , 16 ] Nonetheless, the validated and replicated benefits of probiotic therapy and their impact on survival in the context of GM modulation remain unknown. Similarly, probiotic therapy-related modifications within fungal communities, fungal–bacterial interactions, and associated clinical outcomes in AH are enigmatic. We aimed to study the clinical outcomes and GM changes in AH patients receiving high-dose probiotic infusion (HDPI) compared to corticosteroid therapy (CST). Additionally, survival outcomes compared with matched patients undergoing healthy donor FMT were also analyzed. We also studied mycobiome (fungal) community changes and their interactions among patients with AH in the context of HDPI and CST therapies.

IL-1 Signal Inhibition in Alcohol-Related Hepatitis: a randomised, double-blind, placebo-controlled trial of canakinumab

Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone

Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis

Integrated Transcriptomic and Proteomic Analysis Identifies Plasma Biomarkers of Hepatocellular Failure in Alcohol-Associated Hepatitis

Evidence that extracellular HSPB1 contributes to inflammation in alcohol-associated hepatitis

Emerging Pharmacotherapies in Alcohol-Associated Hepatitis

Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis

T1864 Early Mortality of Alcoholic Hepatitis: A Review of Data from Placebo-Controlled Clinical Trials

Non-Invasive Biomarkers for Differentiating Alcohol Associated Hepatitis from Acute Decompensation in Patients with ALD

In vivo Bruton's tyrosine kinase inhibition attenuates alcohol-associated liver disease by regulating CD84-mediated granulopoiesis

Disrupted balance between pro-inflammatory lipid mediators and anti-inflammatory specialized pro-resolving mediators is linked to hyperinflammation in patients with alcoholic hepatitis

Shc Is Implicated in Calreticulin-Mediated Sterile Inflammation in Alcoholic Hepatitis

Visium spatial transcriptomics and proteomics identifies novel hepatic cell populations and transcriptomic signatures of alcohol‐associated hepatitis

Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity

Outcomes of patients with alcohol-associated hepatitis and acute kidney injury - Results from the HRS Harmony Consortium

Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis

Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis

Cholestatic insult triggers alcohol-associated hepatitis in mice

Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis: Current Status and Future Landscape

Clinical outcomes and associated bacterial and fungal microbiota changes after high dose probiotic therapy for severe alcohol-associated hepatitis: An observational study